Genfit S.A. (GNFT)

NASDAQ: GNFT · Real-Time Price · USD
4.100
+0.080 (1.99%)
Dec 4, 2024, 4:00 PM EST - Market closed
1.99%
Market Cap 197.69M
Revenue (ttm) 86.23M
Net Income (ttm) 23.86M
Shares Out 49.78M
EPS (ttm) 0.47
PE Ratio 8.28
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 8,948
Open 4.100
Previous Close 4.020
Day's Range 4.000 - 4.112
52-Week Range 3.120 - 6.420
Beta 1.12
Analysts Strong Buy
Price Target 13.00 (+217.07%)
Earnings Date Sep 19, 2024

About GNFT

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patien... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Mar 27, 2019
Employees 159
Stock Exchange NASDAQ
Ticker Symbol GNFT
Full Company Profile

Financial Performance

In 2023, Genfit's revenue was 34.48 million, an increase of 31.38% compared to the previous year's 26.25 million. Losses were -28.89 million, 21.8% more than in 2022.

Financial numbers in EUR Financial Statements

Analyst Forecast

According to one analyst, the rating for GNFT stock is "Strong Buy" and the 12-month stock price forecast is $13.0.

Price Target
$13.0
(217.07% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

GENFIT Announces Corporate Updates and Upcoming Participation at The Liver Meeting® 2024

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), November 13, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving th...

21 days ago - GlobeNewsWire

GENFIT Reports Third Quarter 2024 Financial Information

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland); November 7, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the...

27 days ago - GlobeNewsWire

Top 4 Health Care Stocks That May Keep You Up At Night

As of Sept. 24, 2024, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Other symbols: BFRGDOCSGILD
2 months ago - Benzinga

GENFIT: Ipsen's Iqirvo® (Elafibranor) Receives EU Approval as a First-in-Class Treatment for Primary Biliary Cholangitis following U.S. FDA Accelerated Approval

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), September 23, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving t...

2 months ago - GlobeNewsWire

GENFIT: Positive Opinion from EMA Committee for Ipsen's Iqirvo® (elafibranor) in Primary Biliary Cholangitis

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), July 26, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the li...

4 months ago - GlobeNewsWire

GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland) July 9, 2024 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the live...

5 months ago - GlobeNewsWire

GENFIT: New EASL-EASD-EASO Clinical Practice Guidelines for MASLD Include NIS2+® as Key Tool for Detecting At-Risk MASH

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), June 17, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the li...

6 months ago - GlobeNewsWire

GENFIT: Historic Milestone Achieved with U.S. FDA Accelerated Approval of Ipsen's Iqirvo® for Primary Biliary Cholangitis

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), June 10, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the li...

6 months ago - GlobeNewsWire

US FDA approves Genfit and Ipsen's liver disease drug

The U.S. Food and Drug Administration has approved French drugmakers Ipsen and Genfit's drug to treat a chronic inflammatory liver disease, Ipsen said on Monday.

6 months ago - Reuters

GENFIT to Present Latest ACLF Research at EASL Congress™ 2024

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 29, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the liv...

6 months ago - GlobeNewsWire

Genfit: Under The Radar Biotech With Upcoming Catalysts

Genfit S.A. has a PDUFA date of June 10, 2024, by which time the FDA will decide upon whether elafibranor should be approved to treat patients with primary biliary cholangitis. European marketing appr...

6 months ago - Seeking Alpha

GENFIT: May 22, 2024 Combined Shareholders Meeting Results

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 22, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the liv...

7 months ago - GlobeNewsWire

GENFIT Reports First Quarter 2024 Financial Information

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 14, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the liv...

7 months ago - GlobeNewsWire

GENFIT: Publication of the 2024 Extra-Financial Performance Report (fiscal year 2023)

Lille (France), Cambridge (Massachusetts, USA), Zurich (Switzerland), April 25, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company committed to improving the lives of pa...

7 months ago - GlobeNewsWire

GENFIT Annual Combined General Meeting of May 22, 2024 — Availability of Preparatory Documents

Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland); April 15, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the l...

8 months ago - GlobeNewsWire

GENFIT Announces Publication of the 2023 Universal Registration Document and the 2023 Annual Report on Form 20-F

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), April 5, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the li...

8 months ago - GlobeNewsWire

GENFIT Reports Full-Year 2023 Financial Results and Provides Corporate Update

Lille, France; Cambridge, MA; Zurich, Switzerland; April 4, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and...

8 months ago - GlobeNewsWire

GENFIT Announces Revenues and Cash Position as of December 31, 2023

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), February 29, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving th...

9 months ago - GlobeNewsWire

GENFIT Announces 2024 Financial Calendar

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), January 15, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the...

11 months ago - GlobeNewsWire

GENFIT Updates 2024 Outlook Following Acceptance of Elafibranor Filings in Primary Biliary Cholangitis (PBC)

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), December 8, 2023 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the...

1 year ago - GlobeNewsWire

GENFIT Announces Publication in the Journal of Hepatology on the Accurate Performance of NIS2+™ as a Screening Tool for the Enrollment of Patients in MASH Clinical Trials

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), December 6, 2023- GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the ...

1 year ago - GlobeNewsWire

Genfit: Large PBC Market, Liquidity To Await Approval

Genfit is close to possible approval for its drug team-up with Ipsen, with positive Phase 3 readouts having been achieved. The company focuses on developing therapeutic products for liver diseases, cu...

1 year ago - Seeking Alpha

GENFIT Highlights ACLF Development Strategy at “ACLF Day” during AASLD The Liver Meeting® 2023

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), November 16, 2023 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving th...

1 year ago - GlobeNewsWire

GENFIT: Results from Ipsen's ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaking data at AASLD congress and published in New England Journal of Medicine

Paris (France), November 13, 2023 – Ipsen (Euronext: IPN; ADR: IPSEY) and GENFIT (Nasdaq and Euronext: GNFT) today announced full results from the pivotal Phase III ELATIVE® trial, which are being pre...

1 year ago - GlobeNewsWire

GENFIT Reports Third Quarter 2023 Financial Information

Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland); November 9, 2023 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the...

1 year ago - GlobeNewsWire